{
  "id": 2620191,
  "title": "Moderna-Merck Vaccine Cuts Recurrence And Spread of Melanoma, Raises New Treatment Hope",
  "url": "https://urgent.news/2026/08/22/moderna-merck-vaccine-cuts-recurrence-and-spread-of-melanoma-raises",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-22T18:00:00.000Z",
  "source": {
    "name": "Slashdot",
    "slug": "slashdot",
    "url": "https://science.slashdot.org/story/26/08/22/0346210/moderna-merck-vaccine-cuts-recurrence-and-spread-of-melanoma-raises-new-treatment-hope"
  },
  "original_language": "en",
  "account": "Moderna and Merck have announced a promising breakthrough in cancer treatment with a personalized mRNA vaccine that significantly reduces the risk of melanoma recurrence and spread, according to a late-stage trial. This is the first positive result for an mRNA cancer vaccine, which trains the patient's immune system to target specific mutations in cancer cells. When injected, the vaccine prompts the patient's cells to produce copies of these mutations, allowing the immune system to recognize and destroy the cancer. The interim results showed that the treatment, Intismeran, met both its primary goal of reducing cancer recurrence and its secondary goal of preventing tumor spread compared to Keytruda, a widely used immunotherapy drug. Merck and Moderna are already discussing regulatory approval for the treatment, which could be available to thousands of high-risk melanoma patients within a year if approved. This development could mark a new era in treating solid-tumor cancers, with similar approaches being tested against lung, breast, and pancreatic cancers.",
  "summary": "Reuters reports \"a major success in a new field of cancer treatment this week, as Moderna and Merck announced a personalized mRNA cancer vaccine \"reduced the risk of recurrence and spread of melanoma in a late-stage trial\". The vaccine was tested with Merck's widely used immunotherapy drug Keytruda: Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit…",
  "key_points": [
    "Moderna and Merck's mRNA vaccine Intismeran reduces melanoma recurrence.",
    "Vaccine prompts patient's immune system to target specific cancer mutations.",
    "Treatment could be available to high-risk melanoma patients within a year."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}